The Long Road from Laboratory to Pharmacy Shelf: How the FDA Decides Which Drugs Reach American Patients

A Question Worth Asking

If you or someone you care for has ever been diagnosed with a serious illness, you may have encountered a frustrating phenomenon: a treatment available in Europe or Canada that remains inaccessible in the United States, still waiting on what seems like an interminable regulatory process. Alternatively, you may have read about a new medication approved through an expedited pathway and wondered whether speed came at the expense of safety.

These are not abstract policy questions. They have direct implications for patient care, and the answers lie in understanding how the U.S. Food and Drug Administration evaluates new drugs before permitting them to reach American patients.

The Baseline: Standard Approval

The foundation of the FDA's drug review process is the New Drug Application (NDA) for small-molecule drugs, or the Biologics License Application (BLA) for biologic therapies. A manufacturer submitting one of these applications must provide the FDA with comprehensive evidence demonstrating that the drug is both safe and effective for its intended use.

This evidence is generated through a structured clinical trial process:

• Phase I trials involve a small number of healthy volunteers and are primarily designed to assess safety, dosing ranges, and how the body processes the drug.
• Phase II trials expand the participant pool to include individuals with the target condition, testing for preliminary efficacy signals and continuing safety monitoring.
• Phase III trials are large-scale, often randomized and controlled studies designed to definitively establish efficacy and identify adverse effects that may not have appeared in smaller trials.

Under the standard review pathway, the FDA has a target of ten months to complete its evaluation of a submitted application. In practice, the full timeline from initial laboratory work through approval typically spans ten to fifteen years and costs hundreds of millions of dollars — a significant investment that shapes which diseases receive the most pharmaceutical research attention.

The standard pathway prioritizes thoroughness. For medications treating non-life-threatening conditions where existing alternatives exist, this deliberate pace is appropriate. The calculus changes, however, when patients are dying from diseases with no adequate treatment options.

Priority Review: Raising the Urgency Level

When a drug candidate addresses a serious condition and, if approved, would represent a meaningful improvement over available therapies, the FDA may designate it for Priority Review. This designation compresses the standard ten-month review target to six months, without reducing the evidentiary standards required for approval.

Priority Review is a review-speed designation, not an approval guarantee. The manufacturer must still demonstrate safety and efficacy to the same standard. What changes is the FDA's internal resource allocation — more reviewers, faster turnaround — in recognition of the public health importance of the therapy.

Breakthrough Therapy Designation: A More Intensive Partnership

Introduced under the FDA Safety and Innovation Act of 2012, Breakthrough Therapy Designation represents a more hands-on form of FDA engagement than Priority Review alone. To qualify, a drug must be intended for a serious condition, and preliminary clinical evidence must suggest it may offer a substantial improvement over existing therapies on at least one clinically significant endpoint.

When this designation is granted, the FDA commits to intensive guidance throughout the development process — working closely with the manufacturer to identify the most efficient trial designs, offering rolling review of submitted data rather than waiting for a complete application, and providing senior-level agency involvement. The goal is to accelerate development without shortcutting the evidence required for approval.

Since its introduction, Breakthrough Therapy Designation has been applied to treatments for cancers, rare genetic disorders, serious infectious diseases, and mental health conditions, among others. Critics occasionally note that the designation's "substantial improvement" threshold can be difficult to define in early-stage trials, where the evidence base is inherently limited. Proponents counter that the designation's collaborative structure produces better-designed trials, ultimately benefiting both development timelines and the quality of evidence submitted.

Accelerated Approval: Trading Endpoint Certainty for Speed

Perhaps the most debated of the FDA's expedited pathways is Accelerated Approval, which permits the agency to approve a drug based on a surrogate endpoint — a measurable biological marker reasonably likely to predict a clinical benefit — rather than waiting for direct evidence of that clinical outcome.

To illustrate the distinction: a drug might be approved based on evidence that it shrinks tumors (a surrogate endpoint) before long-term survival data (the clinical outcome that actually matters to patients) are available. The manufacturer is required to conduct post-approval confirmatory trials to verify that the surrogate benefit translates into the anticipated clinical benefit.

Accelerated Approval has enabled faster access to treatments for HIV/AIDS, certain cancers, and other serious diseases. It has also generated controversy. In recent years, the FDA has faced scrutiny over cases in which drugs approved under this pathway remained on the market for extended periods without confirmatory trial results, or in which confirmatory data ultimately failed to demonstrate the expected clinical benefit. The 2022 FDA Omnibus Reform Act strengthened the agency's authority to require timely confirmatory trials and to withdraw approvals more efficiently when that evidence is not forthcoming.

For patients, Accelerated Approval drugs represent a calculated trade-off: earlier access to a potentially life-changing treatment, with the understanding that the evidence base is less complete than it would be under standard review.

Fast Track Designation: Opening the Communication Channel

Fast Track Designation is frequently confused with the other expedited pathways, but its primary function is distinct. Rather than accelerating the review clock, Fast Track primarily facilitates more frequent communication between the FDA and the drug developer throughout the development process. It also makes a drug eligible for rolling review, allowing the FDA to evaluate completed sections of the application as they are submitted rather than waiting for the entire dossier.

Fast Track is the broadest of the designations, available to drugs addressing serious conditions with unmet medical needs. A single drug can hold multiple designations simultaneously — Fast Track and Breakthrough Therapy, for instance — and these designations can be granted at any stage of development.

Why Drugs Available Abroad May Not Yet Be Available in the U.S.

The FDA's evidentiary requirements are among the most stringent in the world, a fact that generates a persistent tension with patients who read about treatments approved by the European Medicines Agency (EMA) or Health Canada that remain under review in the United States.

Several factors contribute to this divergence:

• Different evidentiary thresholds: Some regulatory agencies accept surrogate endpoints or smaller trial populations that the FDA would require to be expanded.
• Different approval timelines: The EMA and FDA operate on independent review schedules and do not synchronize their decisions.
• Manufacturer sequencing: Companies sometimes choose to seek approval in one jurisdiction before another based on market size, regulatory complexity, or trial data maturity.
• Post-market monitoring philosophies: Regulatory agencies differ in how they weight pre-approval evidence against post-market surveillance systems.

For patients seeking access to unapproved treatments, the FDA's Expanded Access (Compassionate Use) program offers a pathway to request access to investigational drugs outside of clinical trials, subject to manufacturer consent and FDA authorization. The program is designed for patients with serious conditions who lack adequate alternatives and cannot participate in ongoing trials.

What This Means for Your Treatment Decisions

Understanding the pathway through which a medication was approved provides meaningful context for evaluating its evidence base. A drug approved under standard review after Phase III trials in tens of thousands of patients carries a different evidentiary profile than one approved under Accelerated Approval based on surrogate endpoint data from a few hundred participants.

This does not make one category of drug categorically better or worse — for a patient with a serious diagnosis and limited options, an Accelerated Approval drug may represent the best available treatment. But informed patients benefit from understanding what is known and what remains to be confirmed.

When your prescriber recommends a new medication, it is entirely appropriate to ask which approval pathway it followed, what the confirmatory evidence shows, and whether post-market data has emerged since approval. These questions reflect engaged, informed patient participation — precisely the kind of dialogue that leads to better treatment outcomes.